Retatrutide Delivers the Strongest Obesity Results Yet: Up to 30% Weight Loss
Full Phase 3 results for Eli Lilly's three-hormone obesity drug, published in the New England Journal of Medicine, show average weight loss of 25% at 80 weeks and 30% at 104 weeks at the top dose, with more than a third of participants losing at least 30%. Knee-arthritis pain, sleep apnea and prediabetes all improved sharply — but the trial did not test the drug head-to-head against tirzepatide.